| Market Capitalization (Millions $) |
7,331 |
| Shares
Outstanding (Millions) |
293 |
| Employees |
126,000 |
| Revenues (TTM) (Millions $) |
21,788 |
| Net Income (TTM) (Millions $) |
820 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Fresenius Medical Care Ag
Fresenius Medical Care AG & Co. KGaA (FMC) is a global healthcare provider specializing in the treatment of chronic kidney disease (CKD), dialysis services, and renal care products. It was formed in 1996 when Fresenius SE acquired National Medical Care Inc. and merged it with its dialysis division in Germany. FMC is headquartered in Bad Homburg, Germany, and operates in more than 150 countries worldwide.
The company's primary mission is to enhance the quality of life of patients diagnosed with CKD, providing integrated services and innovative solutions for the early detection and treatment of the disease. FMC provides a broad range of services - including hemodialysis, home dialysis, peritoneal dialysis, and related products - to over 345,000 patients around the world, with a focus on providing high-quality care that is both affordable and accessible. FMC has well over 50 years of experience in dialysis and created the world's first automatic dialysis machine in 196
FMC's strategy is built around its Core Values of Quality, Accountability, Citizenship, and Passion. The company is committed to creating sustainable value for all stakeholders by maintaining a strong focus on operational excellence, continuous improvement, and innovation. The company is committed to delivering responsible business practices, ethically managed operations, and transparent financial reporting as a corporate citizen.
FMC has a diversified business model that includes the development and delivery of products and services, including dialysis machines, dialyzers, renal pharmaceuticals, and healthcare management software. The company's research and development efforts are focused on developing innovative treatments for kidney disease, including the use of stem cells in the regeneration of renal tissue.
FMC is listed on the Frankfurt Stock Exchange and the New York Stock Exchange under the ticker symbol FMS. It is a constituent of the DAX 30 index, the Euro Stoxx 50 index, and the S&P 500 index. The company generates approximately 70% of its revenue from its dialysis business, which remains a critical component of its growth strategy.
In conclusion, Fresenius Medical Care AG & Co. KGaA is a global healthcare provider focused on the treatment of chronic kidney disease. FMC provides a broad range of services and products to over 345,000 patients worldwide while maintaining a focus on operational excellence, innovation, and sustainable value creation. The company's diversified business model includes the development and delivery of dialysis machines, dialyzers, renal pharmaceuticals, healthcare management software, and research focused on developing innovative treatments for kidney disease. FMC's commitment to its core values, ethical practices and responsible corporate citizenship is a testament to the company's leadership as a global healthcare provider.
Company Address: Else-Kr�ner-Strasse 1 Bad Homburg 61352
Company Phone Number: 79 103 33 53 Stock Exchange / Ticker: NYSE FMS
|
4.15%